

Subject Index for Volume 61

(BR) = book review; (E) = editorial; (C) = commentary; (CD) = Chromatin Dynamics '97; (GR) = Gene Regulation '97; (GT) = Gene Therapy '97; (IC) = invited correspondence; (IMS) = Insights from Model Systems; (SG) = Somatic Genetics '97

- Abnormal bone remodeling, 1117
Activin receptor, 60
ADPKD, 547
Adult-onset disorders, 1163
Affected sib pair analysis, 254 (L)
Affective disorder, 1370
Africa, 691
African-American, 402
African Blacks, 1095
Age at onset, 223
Aging, 171
Albers-Schönberg disease, 363
Albinism, oculocutaneous, 1088
 Rufous oculocutaneous, 1095
Alcohol addiction, 481 (IMS)
Allele sharing, 1179
Alpha1A-voltage-dependent calcium channel gene
 (CACNL1A4), 336
American populations, 1413
Amerindians, 505
 mtDNA, 244 (L)
Amish, 231 (L)
AMOVA, 719
Amsterdam criteria, 329
Anchoring fibril, 599
Androgen receptor, 458(L), 1067, 1353
Androgen-sensitivity syndrome, 1067
Anemia, megaloblastic, 1335
Aneuploidy, 651
 Pregnancies, 822
Angelman syndrome, 88, 241 (L), 1342
Animal model, 489 (IMS)
Anterior chamber, 765 (L)
Apolipoprotein (a), 402
Arthrogryposis, 1139
Ashkenazim, 768 (L)
Asian, 462 (L)
Association, 439, 1204 (L)
Association mapping, 734
Association study, 189
Assortative mating, 497, 1169
Ataxia, 1078
 Cerebellar, 1078
ATP7A gene, 233 (L)
Attention deficit/hyperactivity disorder, 449 (L)
Australian Aborigines, 182
Autosomal dominant cerebellar ataxia (ADCA), 336
Autosomal dominant polycystic kidney disease, 1044
Autosomal recessive, 94, 143, 539, 899, 1139
Avellino corneal dystrophy, 1448 (L)
Axenfeld-Rieger anomaly, 765 (L)

Baboons, 489 (IMS)
Balancing selection, 505
Barth syndrome, 862, 868, 1053
Batten disease, 310
Beckwith-Weidemann syndrome, 295, 304
Behavior genetics, 481 (IMS)
 β -oxidation, 1153
Bilateral periventricular nodular heterotopia, 379
Bile acids, 630
Bipolar disorder, 1397
Blindness, 1287
Bottleneck, 1303
Bradley-Terry model, 774 (L), 778 (L)
BRCA1, 761 (L), 1454 (L)
BRCA2, 120
Bronchopulmonary dysplasia, 461 (L)

CAG repeat expansion, 336
Calcium channel, 1078
Calpain 3, 231 (L)
Cancer, 129, 418, 995 (SG), 1006 (IMS), 1234 (E),
 1254
 Breast, 120, 678, 761 (L), 1036, 1254
 Childhood, 1204 (L)
 Colon, 329
 Intestinal, 1327
 Ovarian, 120
 Prostate, 120, 347
 Susceptibility, 1036
 Treatment, 785 (GT)
Candidate gene, 189
Cardiac malformations, 395
Cardiomyopathy, 862, 909, 1053
Carnitine-acylcarnitine carrier, 1239
CCR5, 1261
cDNA, 1318
 Cloning, 1239
CTG repeat, 1445 (L)
Cell cycle, 795 (IMS)
Cell lines, 778 (L)
Centromere(s), 1225 (CD)
Ceroid, 1088
Ceruleplasmin, 317
CFTR mutations, 1200 (L)

- CGG trinucleotide repeat, 961
 Chemokine receptor, 1261
 Children's assent/consent, 1163
 Cholestasis, 630
 Cholesterol, 171
 Chorea-acanthocytosis, 899
 Choreoathetosis, 889
 Chromatids, 23
 Chromatin, 1213 (IMS)
 Chromosomal breakpoint, 620
 Chromosomal instability, 940
 Chromosome 1, 347,363,611,1335
 Chromosome 1p, 642
 Chromosome 1p36 monosomy, 642
 Chromosome 2, 461 (L)
 Chromosome 4, 1405
 Chromosome 5, 1139
 Chromosome 5q, 1450 (L)
 Chromosome 6, 765 (L)
 Chromosome 6p, 924
 Chromosome 6p25, 882
 Chromosome 6q, 1205 (L)
 Chromosome 8, 239 (L)
 Chromosome 9, 928
 Chromosome 9q21, 899
 Chromosome 10q23, 1234 (E)
 Chromosome 14, 1123
 Chromosome 15, 88, 228 (L), 1342
 Chromosome 16, 873, 889
 Chromosome 17, 1131, 1379
 Chromosome 18, 139, 1117, 1397
 Chromosome 18q, 143
 Chromosome 19, 1059, 1327
 Chromosome 19p, 336
 Chromosome 20, 1112
 Chromosome 21, 873
 Chromosome 22q11 deletions, 620
 Chromosome Y, 251 (L)
 Chromosome irradiation, 795 (IMS)
CLN3, 310
CMD gene, 918
 Coalescence time, 980 (L)
COL7A1 mutations, 599
 Collagen, type VII, 599
 Colon, 129
 Combinatorial libraries, 273 (IMS)
 Combined factor V--factor VIII deficiency, 143
 Comparison, 1431
 Complementation analysis, 940
 Complementation group FA-A, 1246
 Complex disease(s), 423, 454 (L), 1379
 Computer simulation, 418
 Conduction-system disease, 909
 Confined placental mosaicism, 461 (L)
 Congenital, 1445 (L)
 Congenital disorder, 620
 Congenital dyserythropoietic anemia type II, 1112
 Congenital ichthyosis, 529
 Consanguineous, 94
 Contiguous-gene-deletion syndrome, 449 (L)
 Control-region sequences, 1413
 Convulsion, 889
 Corneal dystrophy, 1268
 Cornified cell envelope, 581
 Counseling, 282, 1102
 Genetic, 466 (L), 806 (E)
 Cowden disease/syndrome, 1036, 1254
 CpG dinucleotide, 80
 Craniometaphyseal dysplasia, 918
 Cross-linker sensitivity, 940
 CSGE (conformation sensitive gel electrophoresis), 520
 Cultured monocytes, 852
 Cytochrome *c* oxidase, 953

 "Database cloning", 1318
 D-bifunctional protein deficiency, 1153
 D' disequilibrium coefficient, 771 (L)
 Deaf-blindness, 813
 Deafness, 801 (E), 813, 924, 1335
 Deletion(s), 395, 228 (L)
 Deletion mapping, 642
 Dementia, 1131
 Demic diffusion, 251 (L)
 Demographic expansions, 691
 Demographic history, 983 (L)
 Demographic model, 768 (L)
 De novo mutations, 1102
 Dental anomalies, 1405
 Depression, unipolar, 1370
 Developmental delay, 51
DFNA13, 924
 Diabetes, 223, 668, 734, 778 (L), 1335
 Diagnostic testing, 241 (L)
 Digenic, 231 (L)
 DiGeorge syndrome, 620, 1456 (L), 1458 (L)
 Directiveness, 466 (L)
 Disassortative mating, 497
 Disease locus, 1379
 Distal muscular dystrophy, 151
 Divergence rate, 986 (L)
 D-loop, 246 (L)
 DNA
 Dynamics, 1225 (CD)
 Methylation, 80, 1213 (IMS)
 Pooling, 734
 Repair, 995 (SG), 1220 (CD)
 Replication, 1220 (CD)
 Testing, 282
 DNA-PK complex, 795 (IMS)

- Dogs, 475 (IMS)
 Dopamine, 1144
 D4 receptor locus, 238 (L)
 Double-strand break repair, 795 (IMS)
DRD4, 1144
Drosophila, 1006 (IMS)
 Dual-specificity phosphatase, 1234 (E)
 Duplication, 379
 Interstitial, 1342
 Dyskeratosis, 458 (L)
 Dysmorphic features, 1450 (L)
 Dystonia, 928
 Dystrophy, 1287

 E2F, 556
 Early onset, 1370
 Ectodermal dysplasia, 94
 EDS type IV, 1276
 EFE1, 862
 Efficiency, 1189
 Ehlers-Danlos syndrome, 1276
 Ejaculatory ducts, 1200 (L)
 ELAV, 273 (IMS)
 Ellis-van Creveld syndrome, 1405
 Embryos, preimplantation, 33
 Endocardial fibroelastosis, 868
 Endoglin, 68
 Endothelial derived relaxing factor, 354
 Endothelial nitric oxide synthase, 354
eNOS gene, 354
 Epidermal differentiation, 370
 Epidermolysis bullosa, 599, 611
 Epilepsy, 1205 (L)
 Error, 423
 Erythrokeratoderma, 581
 Estimating equations, 189
 Evolution, 462 (L), 983 (L), 986 (L)
 Human, 705
 Exclusion mapping, 634
 Exon skipping, 1276
 Expansion dynamics, 101
 Expression, 33
 Expression system, 590
EXT1, 520
EXT2, 520
 Eye movements, 1078

FAA gene, 1246
 Factor XIII, 529
 Familial, 630
 Cancer, 1123
 Family data, 189
 Fanconi anemia, 940, 1246
 Fatty-acid oxidation, 1239
 Fetal cells, 806 (E)
 Maternal blood, 822

 Finnish population, 1379
 FISH, 16 (E), 51, 379, 651
 Fly, 1006 (IMS)
FMR1, 660, 1362
 Deletion, 961
 FMRP, 1362
 Expression, 961
 Founder effect, 370, 768 (L), 1088
 Fragile X syndrome, 660, 961
 French-Canadians, 768 (L)
 French populations, 678
 Frequency, 1459 (L)
 Friedreich ataxia, 101
 Fructose-1,6-bisphosphatase deficiency, 852
 Full mutation, 1362
 Function, 317

 GAA trinucleotide repeat, 101
 Galactosemia, 590
 GALE, 590
 Gametic disequilibrium, 771 (L)
 GenBank U49897, 1309
 Gene analysis, 1153
 Gene conversion, 9 (E), 40
 Gene-environment interaction, 1189
 Gene mapping, 423, 918, 1268
 Gene regulation, 259 (GR)
 Gene structure, 60
 Gene symbol, 1309
 Gene therapy, 785 (GT), 790 (GT)
 Genetic association, 182, 1144
 Genetic defect, 1287
 Genetic diseases, 768 (L)
 Genetic distances, 980 (L)
 Genetic heterogeneity, 940, 968, 1169
 Genetic isolate, 1379
 Genetic linkage analysis, 873
 Genetic susceptibility, 454 (L)
 Genetic testing, 1163
 Geniospasm, hereditary, 928
 Genodermatosis, 370, 581
 Genome scan(s)/scanning, 430, 899, 810 (E), 830
 Genome screen, 734
 Genome-scan disease locus, 1379
 Genome-mismatch scanning, 111
 Genomewide, 1424
 Genomic imprinting, 88, 304, 1213 (IMS)
 Genomic variation, 40
 Genotype(s), 171, 317, 1309
 Genotype/phenotype association, 282, 1053
 Genotype-phenotype correlation(s), 101, 1078, 1342
 Genotype relative risks, 1424
G4.5, 1053
 Gene mutation, 868
GHR gene, 918
 Glaucoma, 765 (L), 882, 1202 (L)

- GLC1A*, 1202 (L)
 Glucocorticoid response gene, 1202 (L)
 Glycerol, 852
 Glycogen storage disease, 539
 GMS (genome-mismatch scanning), 111
Gooseoid-like sequences, 1456 (L), 1458 (L)
 Granular corneal dystrophy, 1448 (L)
 Growth-hormone receptor gene, 918
 Growth retardation, 461 (L)
 Growth suppression, 556
 Guanine nucleotide-exchange factor, 1287
- H19*, 295
 Hair, 1303
 Hamartoma, 1036
 Haplogroup diversity, 1413
 Haploinsufficiency, 68
 Haplotype analysis, 813
 Haplotype sharing, 430
 Hazard function, 968
 Hearing loss, 924
 Helminth, 182
 Hemizygous deletion, 449 (L)
 Hemophilia, 143
 Hereditary nonpolyposis colorectal cancer, 129, 329
 Hereditary Hemorrhagic Telangiectasia, 60, 68
 Herlitz junctional epidermolysis bullosa, 611
 Hermansky-Pudlak syndrome, 1088
 Heteroduplex analysis, 611
 Heterogeneity, 928
 Heteroplasmy, 1303
 Heterotaxy, 395
 Heterotopia, 379
 Heterozygous, 1405
 High-affinity receptor for IgE, 182
 HIV-1, 1261
 HLA, 494 (E), 497, 454 (L)
 HLA-H, 762 (L)
bMLH1 founder mutation, 129
 Homogeneity, 475 (IMS), 1448 (L)
 Homozygosity, 630
 Homozygosity mapping, 1335
HPC1, 347
HPRT, 33
HTX1, 395
 Human, 934
 Human embryos, 5 (E)
 Human evolution, 1015
 Human migration, 462 (L)
 Human populations, 768 (L)
 Human sperm, 651
 Huntington disease, 945
 Hutterites, 497
 Hyperphenylalaninemia, 1309
 Hypertension, 1459 (L)
 Hypodontia, 94
 Hypohidrotic, 94
- Ichthyosis, 529
 IDDM (insulin-dependent diabetes mellitus), 223, 734
 Identity by descent, 830
 IGDA (iridogoniodysgenesis anomaly), 111
 IgE, 182
IGF2, 295
 Immigration, 705
 Immunomodulatory gene therapy, 785 (GT)
 Imprinting, 295, 304, 1213 (IMS), 1397
 Imprinting mutation, 88
 Inactivation, 458 (L)
 Infectious disease, 968
 Insulin-dependent diabetes mellitus, 223, 734
 Interactions, genetic and reproductive factors, 678
 Intron retention, 1276
 Intronic mutation, 1067
IPW, 388
 Iridogoniodysgenesis anomaly, 111
 Iridogoniodyspasia, 882
 Iris hypoplasia, 765 (L)
 Iron-storage disease, 762 (L)
 Isochromosome, 461 (L)
 Isolated noncompaction of ventricular myocardium (INVM), 868
 Israeli populations, 813
 Italian populations, 1246
- Japan/Japanese, 1202 (L), 1448 (L)
 JC-1, 953
 Junctional epidermolysis bullosa, 611
 Juvenile polyposis, 1254
- Keratin 12, 1268
 Keratinocyte transglutaminase, 529
 Kerato-epithelin mutation, 1448 (L)
 Keratolytic winter erythema, 370
 Khoisan, 980 (L)
 Kidney, 843
 Disease, 547
 Kugelberg-Welander, 151
- Laboratory policies, 1163
 Lactic acidosis, 1318
 Lafora progressive myoclonus epilepsy, 1205 (L)
LAMB3 gene, 611
 Lamellar ichthyosis, 529
 Language affinities, 1011 (E)
 Language families, 1015
 Later Stone Age, 691
 Lattice corneal dystrophy, 1448 (L)
 L-bifunctional protein deficiency, 1153
 Left-right axis, 395
 Legal aspects of testing, 1163
 Leishmaniasis, 968

- Length-biased sampling, 430
 Leukemia, 873
 LGMD2A, 231 (L)
 Limb-girdle muscular dystrophy 2A, 151, 231 (L)
 Linguistics, 1015
 Linkage, 160, 254 (L), 370, 452, 668, 762 (L), 882, 889, 909, 934, 1059, 1131, 1139, 1397, 1431
 Analysis, 120, 139, 143, 336, 418, 423, 430, 748, 810 (E), 918, 1112, 1123, 1169, 1179, 1189, 1327, 1388
 Disequilibrium, 439, 734, 810 (E)
 Mapping, 830
 Exclusion, 239 (L)
 Mapping, 239 (L)
 Lipofuscin, 1088
 Lipoproteins, 402
 Liver, 539, 630
 LOD scores, 418, 1179
 LOH, 512
 Longevity, 1459 (L)
 Loricrin, 581
 Loss of heterozygosity, 995 (SG)
 Lynch syndrome, 329
- M-CSF, 363
 Macular dystrophy, 239 (L)
 Major histocompatibility complex, 505
 Mapping, 151, 379
 Genetic, 830, 1112
 Marker, 189
 Association, 223
 Markov chain Monte Carlo, 748
 MASC (marker association–segregation O^2), 223
 Mate choice, 497, 494 (E)
 Mate selection, 505
 Maternal inheritance, 953
 MDM2, 556
 Measures of disequilibrium, 771 (L)
 Median networks, 691
 Meesmann corneal dystrophy, 1268
 Meiosis, 1 (E), 23
 Meiotic error, 1 (E)
 Mendelian peeling, 748
 Mental retardation, 51, 660, 1450 (L)
 Message therapy, 790 (GT)
 Metabolic bone disease, 1117
 Metanalysis, 1309
 Methylation, 80, 304, 388, 1353, 1220 (CD)
 Methylenetetrahydrofolate reductase gene, 1459 (L)
 Methylglutaconic aciduria, 1053
 MHC (major histocompatibility complex), 454 (L), 494 (E)
 Microdeletions, 51, 1450 (L)
 Breakpoints, 1454 (L)
- Microsatellite, 734
 Markers, 1397
 Polymorphisms, 719
 Middle East, 630
 Middle Stone Age, 691
 Migrations, 1011 (E)
 Mismatch distributions, 980 (L), 983 (L)
 Mismatch-repair genes, 329
 Model systems, 1006 (IMS)
 Model organisms, 273 (IMS), 489 (IMS)
 Model systems, 1006 (IMS)
 Model-free, 254 (L)
 Molecular analysis, 852
 Monkeys, 481 (IMS)
 Mood disorder(s), 1397
 Mosaicism, somatic, 1445 (L)
 Mosaicism, 1293
 Mouse, 801 (E)
 mRNA, 259 (GR)
 mRNA targeting, 790 (GT)
 mt-haplotypes, 244 (L)
 mtDNA, 19 (IC), 246 (L), 251 (L), 691, 953, 980 (L), 986 (L), 1015, 1303, 1413
 Markers, 244 (L)
 Recombination, 19 (IC)
 Multiallele loci, 774 (L), 778 (L)
 multiFISH, 51
 Multilocus FISH analysis, 16 (E)
 Multinodular goiter, 1123
 Multiple exostoses, 520
 Multiple sclerosis, 454 (L), 734, 1379
 Multipoint linkage mapping, 748
 Muscle, 539
 Muscular dystrophy, 909
 Mutation(s), 60, 68, 304, 310, 317, 1309, 1318
 Analysis, 1088, 1246
 Detection, 547, 1044, 1067, 1239, 1268
 Galactosemia, 590
 Hot spot, 80
 Point, 1303
 Rate, 246 (L), 986 (L), 1102
 Retinoblastoma, 282
 Screening, 520
 Mutational mechanism, 1102
 MYOC, 1202 (L)
 Myocilin, 1202 (L)
 Myosins, 801 (E)
 VIIA mutations, 813
 Myotonic dystrophy, 1445 (L)
- Nail dystrophy, 1405
 Native Americans, 246 (L)
 NCL, 310
 Negative assortative mating, 505
 Neocentromere formation, 1225 (CD)

- Neolithic period, 251 (L)
 Neoplasias, 1327
 Neural tube defects, 1204 (L)
 Neuroacanthocytosis, 899
 Neurofibromas, 512
 Neurofibromatosis 2, 512, 1293
 Neuronal ceroid lipofuscinosis, 310
 Neuropathic, 1139
 NF1, 512
 NIDDM, 668
 Niemann-Pick Type D, 139
 Nitric oxide, 354
 Nonbullous congenital ichthyosiformis erythroderma, 529
 Nondirectiveness, 466 (L)
 Nondisjunction, 23
 Nonmedullary thyroid carcinoma, 1123
 Nonparametric, 254 (L), 1388
 Statistics, 1431
 Tests, 1179
 Novelty seeking, 1144
 Nuclear families, 439
 Nuclease sensitivity, 1213 (IMS)
- Obesity, 668
 Occipital horn syndrome, 233 (L)
 Ocular, 882
 Ocular disease(s), 571, 1287
 Oligogenic models, 748
 OMIM: 261600, 1309
 One-G-residue insertion, 852
 Onychodystrophy, 1405
 Oocytes, 1 (E), 23, 33
 Optic atrophy, 934
 Osteochondrodysplasia, 918
 Osteoclast, 1117
 Osteopetrosis, 363
 Ovarian function, 1362
- Paget disease of bone, 1117
 Palmoplantar keratoderma, 370, 581
 Papillary thyroid cancer, 1123
 Paramyxovirus, 1117
 Parasitic disease, 452 (L)
 Parasitic infection, 182
 Paroxysmal choreoathetosis, 889
 Paternal origin, 1102
 PCR, 822
 Pedigree, 934
 Penetrance, 120, 556, 762 (L), 1059
 Peroxisomes, 1153
 Personality disorders, 1144
 Peutz-Jeghers syndrome, 1327
 p57^{KIP2}, 295
 p57^{KIP2}, 304
- Phenotype, 317
 Phosphatase, 1036
 Phosphorylase kinase, 539
 Phylogenetic networks, 980 (L)
 Physical map, 620
 PKD1, 843, 1044
 PKD2, 547
 Placental mosaicism, 1353
 Platelet storage-pool deficiency, 1088
 Polycystic kidney disease, 547, 843, 1000 (SG), 1044
 Polymorphism(s), 171, 705, 761 (L) 1261
 Population(s), 719, 1011 (E), 1459 (L)
 European, 251 (L)
 Expansion, 705, 983 (L), 1413
 Isolated, 830
 Structure, 1015
 Population-based study, 454 (L)
 Positive/negative symptoms, 1388
 Postaxial polydactyly, 1405
 Power, 211, 1189, 1431
 Statistical, 200
 Prader-Willi syndrome, 228, 241 (L), 388, 1342
 Predictive testing, 279 (E), 945
 Predivision, 23
 Preeclampsia, 354
 Pregnancy-induced hypertension, 354
 Pregnancy loss, 160
 Premature ovarian failure, 1362
 Prenatal diagnosis, 806 (E), 822
 Presenile dementia, 1131
 Prevalence, 660
 Primary open-angle glaucoma, 1202 (L)
 Progressive symmetrical erythrokeratoderma, 581
 Prostate cancer, 347
 Protein-truncation test, 1044
 Protein X, 1318
 Pseudoainhum, 581
 Psychological survey, 660
 Psychology, 466 (L)
 Psychomotor retardation, 642
 PTEN, 1234 (E), 1254
 Puerto Rican, 1088
 Pulsed-field gel electrophoresis, 40
 Pyruvate dehydrogenase complex, 1318
- QTL(s), 200, 211
 Quantitative phenotypes, 452 (L)
 Quantitative trait(s), 200, 211, 1189, 1388
- Rad 52, 795 (IMS)
 Random mating, 505
 RB1 gene, 80
 Recombination, 19, 651, 995 (SG)
 Mitochondrial, 19 (IC)
 Recombination fraction, 1189

- Regressive models, 678, 968
 Relative risk ratio, 200, 211
 Renal cystic disease, 843
 Rendu-Osler-Weber syndrome, 68
 Renewal theory, 430
 Reproductive factors, 678
 RER, 329
 Retinal degeneration, 1287
 Retinitis pigmentosa, 571, 1059
 Retinoblastoma, 80, 279 (E), 282, 556
 Rett syndrome, 634
 Reunion paradox, 231 (L)
 Reversible jump Markov chain Monte Carlo, 748
 RFLP, 246 (L)
 Rimmed vacuoles, 151
 Risk reversal, 945
 RNA-protein interactions, 273 (IMS)
 RNA splicing, 1276
 RNA-SSCP, 1246
 RNA stability, 273 (IMS)
RP11, 1059
 RT-PCR, 388
 Rufous oculocutaneous albinism, 1095
- Sample size, 1424
 Sampling variance of D' , 771 (L)
Schistosoma mansoni, 452 (L)
 Schizophrenia, 1388, 1450 (L)
 Schwannoma, 1293
 Schwannomatosis, 1293
 Screening, 279 (E), 660
 Segregation, 223, 651, 1303
 Analysis, 668, 748, 968, 1189, 1370
 Seizures, 642
 Selective sampling, 200, 211
 Seminal vesicles, 1200 (L)
 Semiparametric models, 1179
 Sensorineural deafness, 813
 Serine-threonine kinase receptor, 60
 Serum IgE, 182
 Sex differentiation, 1067
 Sexing, 33
 Sibling pair(s), 402, 423, 439, 1059, 1431
 Method, 200, 211
 Simulation, 189, 1169
 Single-marker evaluation, 1431
 Situs ambiguus, 395
SM1 locus, 452 (L)
SNRPN, 88, 388
 Somatic-cell hybridization, 940
 Somatic mosaicism, 282
 Somatic mutation, 1000 (SG)
 Sperm-derived mtDNA, 953
 Spina bifida, 1204 (L)
 Spinal muscular atrophy, 9 (E), 40, 1102
 Spinocerebellar ataxia type 6 (SCA6), 336
 Splice-site selection, 259 (GR)
 Splice defects, 571
 Splicing mutation, 233 (L)
 SSCA, 547
 Statistics, 254 (L)
 Study design, 211
 Substance dependence, 1144
 Sudden unexpected infants death, 852
 Suicide gene therapy, 785 (GT)
 Survival motor-neuron gene, 1102
 Susceptibility, genetic, 678, 1450 (L)
 Susceptibility gene, 810 (E)
 Symmetric elements, 1454 (L)
 Synaptic transmission, 449 (L)
 Syntaxin 1A, 449 (L)
- Tafazzins, 868
 Tauopathy, 1131
 TDT (transmission/disequilibrium test), 238 (L), 439, 454, 774 (L), 778 (L), 1424
 Testing
 Children, 1163
 Predictive, 945
 Thiamine, 1335
TIGR, 1202 (L)
 Tissue distribution, 1239
 Tourette syndrome, 238 (L)
 TPQ, 1144
 Trabecular meshwork-inducible glucocorticoid response gene, 1202 (L)
 Transcription activation, 761 (L)
 Transforming growth-factor beta receptor, 60
 Transglutaminase, 529
 Translational control, 273 (IMS)
 Translocation, 388, 651
 Transmission disequilibrium test (TDT), 238 (L), 439, 454, 774 (L), 778 (L), 1424
 Trembling chin, 928
 Tremor, 928
 Trichilemmoma mutations, 1036
 Triglyceride, 171
 Trinucleotide repeat, 1362
 Trisomy 21, 822
 Trisomy, 23
TSC2, 843
 Tuberous sclerosis, 843
 Tumor, retinoblastoma, 279 (E)
 therapy, 785 (GT)
 Tumor suppressor(s), 347, 1006 (IMS), 1234 (E), 1293
 Gene, 512, 995 (SG), 1293
 Two-hit model, 1000 (SG)
 Tyrosinase-related protein 1, 1095
 Tyrosine phosphorylation, 1234 (E)
- UBE3A, 88

- UDP-galactose-4-epimerase, 590
Unequal recombination, 228 (L)
Uniparental disomy, 461 (L), 611, 1353
Unipolar depression, 1370
Usher syndrome, 813
- V(D)J recombination, 795 (IMS)
Variable QTL number, 748
Variation
 Genetics, 475 (IMS)
 Human, 1011 (E)
Velo-cardio-facial syndrome, 620, 1456 (L), 1458 (L)
Vervets, 481 (IMS)
VMD1, 239 (L)
- Waiting-time paradox, 430
Weak allele, 556
Weyer acrofacial dysostosis, 1405
Whole-genome studies, 810 (E)
Williams syndrome, 449 (L)
Wilms tumor, 295
- Wilson disease, 317
Worm infestation, 452 (L)
- X chromosome, 458 (L), 634
X inactivation, 5 (E), 160, 634, 1354
X-linked, 571
 Cardiomyopathy, 868
 Gene, 862
X-Y homologous microsatellites, 719
XIST, 5 (E), 33
XLRP, 571
Xq26.2, 395
Xq28, 160, 379, 1053
- Y chromosome, 251 (L), 462 (L)
 Polymorphism, 1015
YAP⁺ Y chromosome, 462 (L)
Yeast (*Saccharomyces cerevisiae*), 590
- Zinc clusters, 1067